Insight journal - Company

Galderma – Derma Specialist prioritizing science driven licensing agreements

Posted on 27 January 2014

Tags: , ,

Galderma is one of the world’s largest dermatology and top 50 pharma companies. Galderma provides medical solutions to a variety of dermatological conditions including acne, rosecea and psoriasis. Based in Switzerland, the company has a strong global workforce of 5,000 employees and distributes its products around 80 countries globally.

It’s no surprise that Galderma has become such a success globally; after all it was formed through a collaboration between proven corporate giants Nestle and L’oreal. The company was born in 1981 after L'Oreal joined forces with Nestle who had previously acquired Alcon who then owned the Owen Dermatology Company. Galderma has since significantly expanded since then and is now scattered around many countries including France, Sweden, Switzerland, Canada, USA, Brazil and Japan with its five R&D Centers and 5 manufacturing sites.

Galderma’s success may be partly down to the fact that over the last decade or so dermatology has become an increasingly popular therapeutic area, conditions such as acne, psoriasis and dermatitis have become more widespread in terms of diagnosis in economically developed nations leading to the demand for medications to rise. Galderma’s top therapeutics include;

  • Azzalure - Muscle relaxant created the botulinum toxin type-A of Dysport, targeted for use in aesthetic indications
  • Cetaphil - Cleansing moisturizing and UV protective products
  • Clobex is indicated for the treatment of inflammatory dermatoses such as psoriasis or atopic dermatitis
  • Differin - Topical retinoid treatment for acne
  • Emervel  - Dermal fillers
  • Epiduo is a gel combining a retinoid with benzoyl peroxide indicated for the treatment of acne
  • Loceryl Nail Lacquer - Antifungal for the treatment of onychomycosis
  • Macrolane - Hyaluronic acid-based filler
  • Rozex / Metrogel -  Cream, gel or lotion developed to treat rosacea
  • Metvix -  is a topical photosensitizer indicated for the treatment of actinic keratosis and superficial basal cell carcinoma.
  • Oracea (doxycycline) – Rosacea treatment
  • Restylane - Range of hyaluronic acid-based products that hydrate the skin.
  • Silkis / Vectical - Topical treatment for plaque psoriasis
  • Tri-Luma – Combination cream treating melasma of the face

Science driven licensing agreements

Partnerships, licensing agreements and acquisitions have been and remain a priority for Galderma; Over the past twenty years the company has signed key deals involving its top products including Metvix, Tri-Luma and Abotulimun toxin type A. In Galderma’s eyes a successful licensing partnership must provide it with access to technologies that extend its existing programs but remain consistent with its research strategies. Through its strategic acquisitions Galderma has acquired major existing brands Oracea (Collagenex Pharmaceuticals), aesthetic and corrective solutions (Q-Med) and Daylong and Excipial (Spirig Pharma). Galderma has assigned three key contacts on its website to review any incoming partnership opportunities from interested parties.

Partnering outreach

Galderma is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Events with Galderma presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with Galderma in person visit Current Partnering’s Event calendar. 

Contacting Galderma for partnering

Galderma can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:  

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events. 

Direct contact: there are several sources of direct contact with Galderma’s business development team

-        Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-        Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. For a list of the three individuals responsible for licensing, please visit this page.

-        LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channels.

Many of Galderma’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Galderma’s Linkedin Page  

Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the partnerships page available on the Galderma’s website for potential

partnering opportunities. 

Raveena Bhambra

* www.Galderma.com

Galderma M&A at Current Agreements                                                  

View all partnering deals for Galderma: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Report: Partnering Agreements with Galderma 2009-2014

More

Summary profile data for Galderma 

M&A activity for Galderma

Partnering activity for Galderma

 

Available reports from Current Partnering

Report: Partnering Agreements with Galderma 2009-2014

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Merger & Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics

 

Available resources for deal coverage for Galderma

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Galderma company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif